Regeneron's Eylea improves vision in diabetic eye condition

(Reuters) - Regeneron Pharmaceuticals Inc's Eylea helped improve the vision of patients with diabetic macular edema (DME) significantly better than laser surgery in a pair of late-stage clinical trials, paving the way for an expanded approval of the sight-saving medicine, the company said on Tuesday. Eylea is already approved to treat wet age-related macular edema, the leading cause of blindness in the elderly. The condition associated with diabetes is the leading cause of blindness in younger and middle aged adults, with potentially more than 6 million treatable patients worldwide, the U.S. ...



via Health News Headlines - Yahoo! News http://news.yahoo.com/regenerons-eylea-improves-vision-diabetic-eye-condition-063128365.html